Ticagrelor

BRILINTA

P2Y12 Platelet Inhibitor

NADAC/unit $0.3205

No Shortage Tier 1: 44.7% 17 Manufacturers 31 ANDAs

Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a histo....

vs. brand BRILINTA: Generic saves up to 97% per unit

Covered Lives

Generic Manufacturers

ALEMBIC PHARMACEUTICALS LTDALKEM LABORATORIES LTDAMNEAL EU LTDAPOTEX INCASTRAZENECA PHARMACEUTICALS LPCHANGZHOU PHARMACEUTICAL FACTORYDR REDDYS LABORATORIES LTDHISUN PHARMACEUTICAL HANGZHOU CO LTDINVAGEN PHARMACEUTICALS INCMACLEODS PHARMACEUTICALS LTDMANKIND PHARMA LTDMSN LABORATORIES PRIVATE LTDMYLAN PHARMACEUTICALS INCPRINSTON PHARMACEUTICAL INCSCIEGEN PHARMACEUTICALS INCSUNSHINE LAKE PHARMA CO LTDTARO PHARMACEUTICAL INDUSTRIES LTDWATSON LABORATORIES INC

Explore in the Ecosystem

rxsaver.aiCompare prices for Ticagrelor drfinder.aiFind doctors who prescribe Ticagrelor rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Ticagrelor

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.